Edition:
India

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

2.30USD
24 Nov 2017
Change (% chg)

$0.05 (+2.22%)
Prev Close
$2.25
Open
$2.25
Day's High
$2.30
Day's Low
$2.20
Volume
120,473
Avg. Vol
157,053
52-wk High
$6.05
52-wk Low
$1.50

Select another date:

Thu, Nov 9 2017

BRIEF-Sorrento Therapeutics files for mixed shelf of upto $350 mln

* Sorrento Therapeutics Inc files for mixed shelf of upto $350 million - SEC filing‍​ Source text: [http://bit.ly/2yLg1nW] Further company coverage:

BRIEF-Sorrento Therapeutics- ‍Terminated​ deal with Semnur Pharma to purchase all its issued and outstanding equity

* Sorrento Therapeutics - ‍ co, unit Semnur Pharmaceuticals terminated​ deal by which unit would, purchase all of issued and outstanding equity of Semnur Source text: (http://bit.ly/2xYZewg) Further company coverage:

BRIEF-Sorrento Therapeutics files for resale by selling stockholders of up to 754K shares of common stock - SEC filing‍​

* Sorrento Therapeutics Inc - files for resale by selling stockholders of up to 754,930 shares of common stock - SEC filing‍​ Source text: (http://bit.ly/2xTIxlX) Further company coverage:

BRIEF-FDA acknowledges receipt of Sorrento Therapeutics Inc's NDA for Ztlido

* Fda acknowledges receipt of Sorrento Therapeutics Inc, NDA for Ztlido; PDUFA date set for February 28, 2018

BRIEF-Sorrento Therapeutics submits NDA for Ztlido

* Sorrento Therapeutics Inc submits NDA for Ztlido next-generation lidocaine patch

BRIEF-ABG Management's Yu Fan reports 12.2 pct stake in Sorrento Therapeutics as of July 10

* ABG Management's Yu Fan reports 12.2 percent stake in Sorrento Therapeutics as of July 10 - SEC filing

BRIEF-SORRENTO THERAPEUTICS ANNOUNCES DISMISSAL OF LAWSUITS

* SORRENTO THERAPEUTICS INC SAYS DISMISSAL OF ALL CLAIMS AGAINST SORRENTO AND ITS DIRECTORS CONTAINED IN LAWSUITS BROUGHT BY WILDCAT LIQUID ALPHA, LLC Source text for Eikon: Further company coverage:

BRIEF-Sorrento Therapeutics to contribute immuno-oncology and cellular therapy intellectual property, assets to Celularity

* Sorrento Therapeutics - co, unit executed definitive agreement to contribute certain immuno-oncology and cellular therapy intellectual property, assets to Celularity Source text for Eikon: Further company coverage:

Select another date: